Recombinant attenuated clostridium organisms and vaccine
AssigneeIntervet Inc.
InventorsMark D. Cochran, Gary R. Petersen, Stephen V. Lair, Richard M. Synenki
Life of this patent
Estimating the term…
Abstract
The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.
Claims35
A nucleic acid molecule that encodes a substantially nontoxic mutein of Clostridium perfringens alpha-toxin;
- wherein the mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO:
- 3 minus at least 9 consecutive amino acid residues;
- and wherein one of the deleted amino acid residues is His68.
A substantially nontoxic mutein of Clostridium perfringens alpha-toxin;
- wherein the mutein alpha-toxin comprises the amino acid sequence of SEQ ID NO:
- 3 minus at least 9 consecutive amino acid residues;
- and wherein one of the deleted amino acid residues is His68.
A Clostridium perfringens organism that is CPERF/ΔαToxin 365-054 having ATCC Deposit No. PTA7364.
A Clostridium perfringens organism that is CPERF/ΔαToxin 365-053 having ATCC Deposit No. PTA7365.
Dependencies are inferred from the claim text.